β-肾上腺素能受体阻滞剂在阿尔茨海默病中的作用：潜在的遗传和细胞信号转导机制。
The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.
机构信息
Vietnamese American Medical Research Foundation, Westminster, California, CA 92683, USA.
出版信息
Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):427-39. doi: 10.1177/1533317513488924. Epub 2013 May 20.
Abstract
According to genetic studies, Alzheimer's disease (AD) is linked to beta-adrenergic receptor blockade through numerous factors, including human leukocyte antigen genes, the renin-angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate. Beta-adrenergic receptor blockade is also implicated in AD due to its effects on matrix metalloproteinases, mitogen-activated protein kinase pathways, prostaglandins, cyclooxygenase-2, and nitric oxide synthase. Beta-adrenergic receptor blockade may also have a significant role in AD, although the role is controversial. Behavioral symptoms, sex, or genetic factors, including Beta 2-adrenergic receptor variants, apolipoprotein E, and cytochrome P450 CYP2D6, may contribute to beta-adrenergic receptor blockade modulation in AD. Thus, the characterization of beta-adrenergic receptor blockade in patients with AD is needed.
摘要
根据遗传研究，阿尔茨海默病（AD）通过多种因素与β-肾上腺素能受体阻断有关，包括人类白细胞抗原基因、肾素-血管紧张素系统、多聚（腺嘌呤二核苷酸核糖）聚合酶 1、神经生长因子、血管内皮生长因子和烟酰胺腺嘌呤二核苷酸磷酸的还原形式。β-肾上腺素能受体阻断也与 AD 有关，因为它对基质金属蛋白酶、有丝分裂原激活蛋白激酶途径、前列腺素、环氧化酶-2 和一氧化氮合酶有影响。β-肾上腺素能受体阻断在 AD 中也可能具有重要作用，尽管作用存在争议。行为症状、性别或遗传因素，包括β2-肾上腺素能受体变体、载脂蛋白 E 和细胞色素 P450 CYP2D6，可能有助于 AD 中β-肾上腺素能受体阻断的调节。因此，需要对 AD 患者的β-肾上腺素能受体阻断进行特征描述。
相似文献
1
The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.
Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):427-39. doi: 10.1177/1533317513488924. Epub 2013 May 20.
2
The role of β-adrenergic blockers in Parkinson's disease: possible genetic and cell-signaling mechanisms.
Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):306-17. doi: 10.1177/1533317513488919. Epub 2013 May 21.
3
Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer's Disease.
Neurobiol Dis. 2020 Dec;146:105089. doi: 10.1016/j.nbd.2020.105089. Epub 2020 Sep 22.
4
The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.
Cancer Manag Res. 2012;4:431-45. doi: 10.2147/CMAR.S39153. Epub 2012 Dec 18.
5
Roles of β-adrenergic receptors in Alzheimer's disease: implications for novel therapeutics.
Brain Res Bull. 2011 Feb 1;84(2):111-7. doi: 10.1016/j.brainresbull.2010.11.004. Epub 2010 Dec 1.
6
β-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: a new paradigm for prognosis and therapy?
J Alzheimers Dis. 2013;34(2):341-7. doi: 10.3233/JAD-121813.
7
Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling.
J Biol Chem. 2007 Nov 9;282(45):32719-29. doi: 10.1074/jbc.M706815200. Epub 2007 Sep 12.
8
Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.
Circulation. 2003 Sep 30;108(13):1611-8. doi: 10.1161/01.CIR.0000092166.30360.78. Epub 2003 Sep 8.
9
Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons.
J Neurochem. 2003 Aug;86(4):907-16. doi: 10.1046/j.1471-4159.2003.01909.x.
10
Effects of beta-blockade on beta-adrenergic receptors and signal transduction.
J Cardiovasc Pharmacol. 1989;14 Suppl 5:S6-12.
引用本文的文献
1
Exploring the Therapeutic Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) in Individuals With Alzheimer's Disease: A Comprehensive Narrative Review.
Cureus. 2025 May 27;17(5):e84885. doi: 10.7759/cureus.84885. eCollection 2025 May.
2
Implication of Central β Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease.
Arch Pharm (Weinheim). 2025 Apr;358(4):e2400750. doi: 10.1002/ardp.202400750.
3
Deciphering the Role of Adrenergic Receptors in Alzheimer's Disease: Paving the Way for Innovative Therapies.
Biomolecules. 2025 Jan 15;15(1):128. doi: 10.3390/biom15010128.
4
Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's Disease.
J Parkinsons Dis. 2024;14(6):1149-1161. doi: 10.3233/JPD-240039.
5
Association between Incidence of Prescriptions for Alzheimer's Disease and Beta-Adrenoceptor Antagonists: A Prescription Sequence Symmetry Analysis.
Pharmaceuticals (Basel). 2023 Dec 6;16(12):1694. doi: 10.3390/ph16121694.
6
The old second messenger cAMP teams up with novel cell death mechanisms: potential translational therapeutical benefit for Alzheimer's disease and Parkinson's disease.
Front Physiol. 2023 Jun 19;14:1207280. doi: 10.3389/fphys.2023.1207280. eCollection 2023.
7
Zebrafish Larvae Position Tracker (Z-LaP Tracker): a high-throughput deep-learning behavioral approach for the identification of calcineurin pathway-modulating drugs using zebrafish larvae.
Sci Rep. 2023 Feb 23;13(1):3174. doi: 10.1038/s41598-023-30303-w.
8
Identification and immune characteristics of molecular subtypes related to protein glycosylation in Alzheimer's disease.
Front Aging Neurosci. 2022 Nov 2;14:968190. doi: 10.3389/fnagi.2022.968190. eCollection 2022.
9
Pharmacological activation of the C5a receptor leads to stimulation of the β-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer's disease.
Front Immunol. 2022 Aug 26;13:947071. doi: 10.3389/fimmu.2022.947071. eCollection 2022.
10
β-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy.
Life Sci Alliance. 2021 Dec 3;5(3). doi: 10.26508/lsa.202101183. Print 2022 Mar.
本文引用的文献
1
APOE ε4 increases risk for dementia in pure synucleinopathies.
JAMA Neurol. 2013 Feb;70(2):223-8. doi: 10.1001/jamaneurol.2013.600.
2
Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?
N Engl J Med. 2013 Jan 31;368(5):455-64. doi: 10.1056/NEJMra1106180.
3
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.
Nat Rev Neurol. 2013 Feb;9(2):106-18. doi: 10.1038/nrneurol.2012.263. Epub 2013 Jan 8.
4
Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration.
Int J Neuropsychopharmacol. 2013 Jul;16(6):1351-60. doi: 10.1017/S1461145712001393. Epub 2012 Nov 30.
5
Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease.
Alzheimers Dement. 2013 Sep;9(5):512-8. doi: 10.1016/j.jalz.2012.06.007. Epub 2012 Nov 8.
6
Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease.
J Alzheimers Dis. 2013;33(4):1147-56. doi: 10.3233/JAD-2012-120904.
7
Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity.
J Alzheimers Dis. 2013;33(3):823-9. doi: 10.3233/JAD-2012-121528.
8
Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β.
Acta Anaesthesiol Scand. 2013 Jan;57(1):82-8. doi: 10.1111/j.1399-6576.2012.02769.x. Epub 2012 Sep 24.
9
The dementia of cardiac disease.
Curr Cardiol Rep. 2012 Dec;14(6):732-40. doi: 10.1007/s11886-012-0304-8.
10
Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production.
Exp Biol Med (Maywood). 2012 Sep;237(9):1039-44. doi: 10.1258/ebm.2012.012022. Epub 2012 Sep 3.
Zotero 插件